Pharmacological Profile of Different Quercetin Formulations

This study aims to evaluate the pharmacokinetics of quercetin in healthy participants after the administration of different formulations in a single- and multiple-dose phase. In the single-dose study, plasma uptake (AUC0-24 and Cmax) of standard quercetin is compared with that of LipoMicel®-a novel food-grade delivery form of quercetin. In the multiple dose study, accumulating plasma concentrations of formulated quercetin are observed over 72hrs, after repeated doses of LipoMicel treatments (AUC0-72).At least ten healthy adults participate in an open-label, diet-controlled, crossover, plasma uptake study. Participants receive three different doses (250 mg, 500 mg or 1000 mg) of quercetin aglycone orally.

Inclusion Criteria:age 18-65healthy, good physical conditionExclusion Criteria:pregnancy or breast-feedinggastrointestinal conditions (acute or chronic)liver disease (acute or chronic)kidney disease (acute or chronic)cardiovascular disease (acute or chronic)hematological diseasediabetesallergy or intolerance to glutenallergy or intolerance to quercetinuse of any form of nicotine or tobacco, CBD/THCalcohol and substance abuse historyuse of medications (e.g., anti-inflammatory)use of quercetin supplementsparticipation in another investigational study